Literature DB >> 31656813

Stereotactic ablative radiotherapy for operable stage I non-small cell lung cancer: not ready for prime time.

James G Connolly1, Gregory D Jones1, Raul Caso1, David R Jones1.   

Abstract

Entities:  

Year:  2019        PMID： 31656813      PMCID： PMC6789327          DOI： 10.21037/atm.2019.08.40

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  13 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer.

Authors:  Didier Lardinois; Paul De Leyn; Paul Van Schil; Ramon Rami Porta; David Waller; Bernward Passlick; Marcin Zielinski; Toni Lerut; Walter Weder
Journal:  Eur J Cardiothorac Surg       Date:  2006-09-12       Impact factor: 4.191

Review 3.  Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma.

Authors:  Nam P Nguyen; Linda Garland; James Welsh; Russ Hamilton; Deirdre Cohen; Vincent Vinh-Hung
Journal:  Cancer Treat Rev       Date:  2008-07-26       Impact factor: 12.111

4.  Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.

Authors:  Robert D Timmerman; Rebecca Paulus; Harvey I Pass; Elizabeth M Gore; Martin J Edelman; James Galvin; William L Straube; Lucien A Nedzi; Ronald C McGarry; Cliff G Robinson; Peter B Schiff; Garrick Chang; Billy W Loo; Jeffrey D Bradley; Hak Choy
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

5.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

Review 6.  Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.

Authors:  Matthew D Hellmann; Jamie E Chaft; William N William; Valerie Rusch; Katherine M W Pisters; Neda Kalhor; Apar Pataer; William D Travis; Stephen G Swisher; Mark G Kris
Journal:  Lancet Oncol       Date:  2014-01       Impact factor: 41.316

7.  Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation.

Authors:  Alan W Katz; Sheema Chawla; Zhenhong Qu; Randeep Kashyap; Michael T Milano; Aram F Hezel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-13       Impact factor: 7.038

8.  Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance.

Authors:  Feiran Lou; James Huang; Camelia S Sima; Joseph Dycoco; Valerie Rusch; Peter B Bach
Journal:  J Thorac Cardiovasc Surg       Date:  2012-11-03       Impact factor: 5.209

9.  Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

Authors:  David A Palma; Timothy K Nguyen; Alexander V Louie; Richard Malthaner; Dalilah Fortin; George B Rodrigues; Brian Yaremko; Joanna Laba; Keith Kwan; Stewart Gaede; Ting Lee; Aaron Ward; Andrew Warner; Richard Inculet
Journal:  JAMA Oncol       Date:  2019-05-01       Impact factor: 31.777

10.  Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.

Authors:  Malolan S Rajagopalan; Dwight E Heron; Rodney E Wegner; Herbert J Zeh; Nathan Bahary; Alyssa M Krasinskas; Barry Lembersky; Randall Brand; A James Moser; Annette E Quinn; Steven A Burton
Journal:  Radiat Oncol       Date:  2013-10-31       Impact factor: 3.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.